VVOS Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
5.1M
+34.4%
3.8M
-43.6%
6.8M
+77.6%
3.8M
+26.7%
3.0M
Cost of Revenue
2.1M
+149.0%
836.0K
-70.6%
2.8M
+66.4%
1.7M
+13.5%
1.5M
Gross Profit
3.1M
+2.4%
3.0M
-24.1%
3.9M
+86.6%
2.1M
+39.8%
1.5M
Operating Expenses
9.7M
+3.2%
9.4M
+8.1%
8.7M
+24.3%
7.0M
+28.5%
5.4M
R&D
0
0
0
0
0
SG&A
9.2M
+3.3%
8.9M
+7.7%
8.3M
+24.3%
6.7M
+27.0%
5.3M
Operating Income
-6615000
-3.7%
-6382000
-34.8%
-4734000
+2.7%
-4865000
-24.2%
-3918000
EBITDA
-6161000
-3.7%
-5940000
-36.6%
-4350000
+4.6%
-4559000
-21.9%
-3741000
Net Income
-7751000
-11.5%
-6954000
-28.8%
-5400000
-7.7%
-5013000
-29.7%
-3864000
EPS (Basic)
$-0.52
+5.5%
$-0.55
-12.2%
$-0.49
+10.9%
$-0.55
-22.2%
$-0.45
EPS (Diluted)
$-0.52
+5.5%
$-0.55
-12.2%
$-0.49
+10.9%
$-0.55
-22.2%
$-0.45
Shares (Diluted)
14.6M
+17.5%
12.4M
+13.6%
11.0M
+20.6%
9.1M
+5.7%
8.6M
Vivos Therapeutics (VVOS) โ€” Financials